TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31060632

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29103826

Group type: EXPERIMENTAL
Intervention: 64 Gy (32 fractions) salvage radiation therapy (sRT)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: 70 Gy (35 fractions) salvage radiation therapy (sRT)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (surveillance)
Number of subjects: 344
Study: 27363506

Group type: EXPERIMENTAL
Intervention: Lacosamide (200 mg b.i.d.)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 24786948

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 23199590

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside for 120 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo for 24 weeks followed by GM1 for 96 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside and placebo groups
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside for 24 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Extended GM1 use (up to 120 weeks)
Number of subjects: 77
Study: 19940014

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (FBSF) at doses of 200-1200 microg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18410553

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metformin 1.5 g daily
Number of subjects: 20
Study: 19127595

Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg/day)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg with each dose of levodopa)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 16390023

Group type: EXPERIMENTAL
Intervention: 99mTc-MIBI whole body scintiscan
Number of subjects: 43
Study: 11210394

Group type: EXPERIMENTAL
Intervention: Pantoprazole (0.12 to 1.15 mg/kg, i.v. for rats; 20 to 120 mg, i.v. and oral for humans)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9233868

Group type: EXPERIMENTAL
Intervention: Isoniazid (6 months of prophylactic treatment)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Placebo (6 months of treatment)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study: 8214650

Group type: EXPERIMENTAL
Intervention: Propofol infusion (50 mg/min for induction followed by 100 micrograms.kg‐1.min‐1 for maintenance)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Etomidate (8 mg/min and 20 micrograms.kg‐1.min‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 40
Study: 3312591

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once daily)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 11207836

Group type: EXPERIMENTAL
Intervention: Aging (age groups)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Placebo (control group from NORASEPT II)
Number of subjects: 930
Study: 31688575

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg, once yearly for 2 years)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Placebo (once yearly for 2 years)
Number of subjects: 665
Study: 29541551

Group type: EXPERIMENTAL
Intervention: Immediate postpartum LNG IUD insertion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Delayed insertion of LNG IUD (4-6 weeks postpartum)
Number of subjects: 11
Study: 26743105

Group type: EXPERIMENTAL
Intervention: Standard dissection
Number of subjects: 72

Group type: COMPARATOR
Intervention: Limited dissection
Number of subjects: 72
Study: 24411976

Group type: EXPERIMENTAL
Intervention: 400 µg/kg oral ivermectin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22244706

Group type: EXPERIMENTAL
Intervention: 24 weeks of transdermal nicotine patch therapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: 8 weeks of transdermal nicotine patch therapy
Number of subjects: 139
Study: 20150302

Group type: EXPERIMENTAL
Intervention: Mixed injection of 0.2 units/kg lispro and 0.4 units/kg glargine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Separate injections of 0.2 units/kg lispro and 0.4 units/kg glargine
Number of subjects: 11
Study: 17634921

Group type: EXPERIMENTAL
Intervention: Computer-assisted implantation (group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional implantation (group B)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 62
Study: 15940076

Group type: EXPERIMENTAL
Intervention: Minilaparotomy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Traditional laparotomy
Number of subjects: 99
Study: 12486429

Group type: EXPERIMENTAL
Intervention: 5-mg dose of rosuvastatin
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: 10-mg dose of rosuvastatin
Number of subjects: 412

Group type: COMPARATOR
Intervention: 10-mg dose of atorvastatin
Number of subjects: 412
Study: 9798037

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8620948

Group type: EXPERIMENTAL
Intervention: Angiotensin II 2 ng.kg‐1.min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Angiotensin II 1 ng.kg‐1.min
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Angiotensin II alone (in vitro)
Number of subjects: 7
Study: 2674043

Group type: EXPERIMENTAL
Intervention: Nit removal system with formic acid cream rinse
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control section (no treatment)
Number of subjects: 24
Study: 174041

Group type: EXPERIMENTAL
Intervention: Hexamethyl‐melamine (NSC 13875)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Dibromodulcitol (NSC 104800)
Number of subjects: 250
Study: 31938698

Group type: EXPERIMENTAL
Intervention: Talus stabilization taping (TST)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ankle kinesio taping
Number of subjects: 22
Study: 29231476

Group type: EXPERIMENTAL
Intervention: Heat-reinforcing needling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medication (sodium selenite, ibuprofen, vitamin C)
Number of subjects: 60
Study: 24612063

Group type: EXPERIMENTAL
Intervention: Organ-transplanted patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control subjects (healthy)
Number of subjects: 13
Study: 22890641

Group type: EXPERIMENTAL
Intervention: Nicardipine prolonged-release implants (NPRIs) containing 4 mg of nicardipine placed in the cistern of the cerebral arteries during surgery.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicardipine prolonged-release implants (NPRIs)
Number of subjects: 0
Study: 21391429

Group type: EXPERIMENTAL
Intervention: Fenofibrate immediate release tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dissolution/permeation (D/P) system
Number of subjects: 0
Study: 19219669

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy treatment
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Initial Urine Drug Screen (UDS) results
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cocaine Selective Severity Assessment (CSSA) scores
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Initial self-reported cocaine use in past 30 days
Number of subjects: 164

Group type: COMPARATOR
Intervention: Cocaine craving, cocaine composite scores, alcohol craving, alcohol withdrawal symptoms, alcohol composite scores
Number of subjects: 164
Study: 16527634

Group type: EXPERIMENTAL
Intervention: Injection molded elastomeric chains
Number of subjects: 24

Group type: COMPARATOR
Intervention: Die-cut stamped elastomeric chains
Number of subjects: 24
Study: 12873923

Group type: COMPARATOR
Intervention: ondansetron 100 micro g/kg IV
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: dolasetron 350 micro g/kg IV
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: dolasetron 45 micro g/kg IV
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: dolasetron <350 micro g/kg
Number of subjects: 204
Study: 10232442

Group type: EXPERIMENTAL
Intervention: Severe asthma group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Mild asthma group
Number of subjects: 56
Study: 10172689

Group type: EXPERIMENTAL
Intervention: Standard mental health care augmented by the behavioral skills intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified 12-step recovery
Number of subjects: 0
Study: 1928657

Group type: EXPERIMENTAL
Intervention: Antigen-antibody complexes at different ratios and dosages
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo carrier buffer alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Antigen-antibody complexes (previous season treatment)
Number of subjects: 38
Study: 6886901

Group type: EXPERIMENTAL
Intervention: ORS90 (90 mmol Na/L)
Number of subjects: 22

Group type: COMPARATOR
Intervention: ORS40 (40 mmol Na/L)
Number of subjects: 22
Study: 30398221

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conventional epidural analgesia (non-PCEA)
Number of subjects: 111
Study: 30763599

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 28370532

Group type: EXPERIMENTAL
Intervention: Partial rapid eye movement sleep deprivation (REMD group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal amount of rapid eye movement sleep (CTL group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fast sleep spindles
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Slow sleep spindles
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rapid eye movement duration and density
Number of subjects: 14
Study: 26884439

Group type: EXPERIMENTAL
Intervention: Insulin deprivation and endotoxin administration (KET)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Insulin‐controlled euglycemia
Number of subjects: 9
Study: 25526951

Group type: EXPERIMENTAL
Intervention: Oral granulated Chinese herbal medicine YXBCM01 plus topical calcipotriol 0.005%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral YXBCM01 placebo plus topical calcipotriol 0.005%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 22991449

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19196819

Group type: EXPERIMENTAL
Intervention: SNP rs833058
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: SNP rs4711750
Number of subjects: 458
Study: 17133417

Group type: EXPERIMENTAL
Intervention: Tailored interactive computer instruction
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Targeted video
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 344
Study: 16335699

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) supplementation (3.6 g per day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 24
Study: 11740718

Group type: EXPERIMENTAL
Intervention: Oral itraconazole (200 mg per day)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 129
Study: 9635614

Group type: EXPERIMENTAL
Intervention: Psychiatric treatment in addition to physical treatment (experimental group, N = 86)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Physical treatment alone (control group, N = 42)
Number of subjects: 194
Study: 9053564

Group type: EXPERIMENTAL
Intervention: Pulsed-field gel electrophoresis (PFGE) of chromosomal DNA fragments
Number of subjects: 50
Study: 3180674

Group type: EXPERIMENTAL
Intervention: 300 ml 50% w/v baritop and effervescent tablets
Number of subjects: 113

Group type: COMPARATOR
Intervention: 300 ml 100% w/v baritop with 10 ml of Gastrografin and effervescent tablets
Number of subjects: 113
Study: 31380442

Group type: EXPERIMENTAL
Intervention: Diadynamic current (DD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between DD and TENS
Number of subjects: 40
Study: 28981596

Group type: EXPERIMENTAL
Intervention: Early mobilization postoperative programme based on supervised aerobic exercise, resistance and flexibility training
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard rehabilitation care
Number of subjects: 108
Study: 25839137

Group type: EXPERIMENTAL
Intervention: SAR(10G)=2 W/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SAR(10G)=0.2 W/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 24
Study: 24206457

Group type: EXPERIMENTAL
Intervention: Combination therapy with lisinopril (10 to 40 mg per day)
Number of subjects: 1448

Group type: COMPARATOR
Intervention: Monotherapy with losartan (100 mg per day)
Number of subjects: 1448

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1448
Study: 21292243

Group type: EXPERIMENTAL
Intervention: Cue-exposure treatment (CET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 19636278

Group type: EXPERIMENTAL
Intervention: motavizumab (3, 15, or 30 mg/kg intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 17555930

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Real-time 3-dimensional echocardiography (RT-3DE)
Number of subjects: 39
Study: 15082726

Group type: COMPARATOR
Intervention: D1 lymph node dissection
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: D2 lymph node dissection
Number of subjects: 1078
Study: 11383457

Group type: EXPERIMENTAL
Intervention: Treatment based on correlation between tumor size and stage of molecular-genetical disorders
Number of subjects: 0
Study: 9401505

Group type: EXPERIMENTAL
Intervention: Test Diet (TD): a combination of a semi-solid pap (maize flour, black beans, oil) and a liquid gruel, Incaparina (maize flour, cotton seed flour, sugar), in addition to breast-milk and other home foods (n = 45 episodes) for 14 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual home feeding (HF) (n = 54 episodes)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (TD and HF)
Number of subjects: 90
Study: 8123349

Group type: EXPERIMENTAL
Intervention: Proactive counseling protocol combined with a 2-week follow-up mailout; 6-minute proactive telephone counseling.
Number of subjects: 1831

Group type: EXPERIMENTAL
Intervention: Proactive counseling protocol (intervention) at one test site.
Number of subjects: 1831

Group type: COMPARATOR
Intervention: Control group (usual service without proactive counseling).
Number of subjects: 1831
Study: 2441156

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 100 micrograms of alpha‐hANP
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control subcutaneous injection (placebo)
Number of subjects: 8
Study: 2697238

Group type: EXPERIMENTAL
Intervention: pH-adjusted 2-chloroprocaine in sitting position
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: pH-adjusted 2-chloroprocaine in supine position
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control solution in sitting position
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control solution in supine position
Number of subjects: 4
Study: 31137991

Group type: EXPERIMENTAL
Intervention: Energy drink A
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Energy drink B
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Energy drinks (A and B combined)
Number of subjects: 34
Study: 28557655

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) eye drops
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Crosslinked Hyaluronic Acid (CLHA) eye drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of SRI and SAI between SSDE and control groups
Number of subjects: 40
Study: 24910149

Group type: EXPERIMENTAL
Intervention: Identity priming
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: N400 priming
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Priming
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Posterior-P1 amplitude
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Frontal/temporal-P1 amplitude
Number of subjects: 2
Study: 24228867

Group type: EXPERIMENTAL
Intervention: Physiotherapy and occupational therapy delivered six days a week (Monday through Saturday)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Physiotherapy and occupational therapy delivered five days a week (Monday through Friday)
Number of subjects: 996
Study: 21604466

Group type: EXPERIMENTAL
Intervention: Medical treatment with clarithromycin, alkaline nasal douche, and intranasal mometasone furoate for 12 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Surgical treatment (adenoidectomy, tonsillectomy, or ESS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Adenoidectomy (n = 19), adenoidectomy and tonsillectomy (n = 10), ESS (n = 8)
Number of subjects: 72
Study: 18097460

Group type: EXPERIMENTAL
Intervention: ThinOptX lens
Number of subjects: 58

Group type: COMPARATOR
Intervention: Acrysof lens
Number of subjects: 58
Study: 17100757

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study: 15503036

Group type: EXPERIMENTAL
Intervention: Amplatz thrombectomy device (ATD)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Surgical thromboembolectomy (ST)
Number of subjects: 174
Study: 11579852

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HOT), administered once daily for 10 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous vasodilator, administered for 10 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HOT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous vasodilator
Number of subjects: 50
Study: 9383502

Group type: EXPERIMENTAL
Intervention: Topical Skin Protectant (TSP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no TSP application)
Number of subjects: 10
Study: 7970925

Group type: EXPERIMENTAL
Intervention: Aerosolized furosemide (1.0 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Aerosolized normal saline (placebo)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (0.15 mg/kg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination of albuterol and furosemide
Number of subjects: 29
Study: 3297594

Group type: EXPERIMENTAL
Intervention: Dihydroxydibutylether (DHBE), 900 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30071296

Group type: EXPERIMENTAL
Intervention: Daily IGRT
Number of subjects: 470

Group type: COMPARATOR
Intervention: Weekly IGRT
Number of subjects: 470
Study: 27070112

Group type: EXPERIMENTAL
Intervention: Paper tape applied to blister-prone areas or randomly selected locations on the foot
Number of subjects: 128

Group type: COMPARATOR
Intervention: Untaped areas of the same foot (Control)
Number of subjects: 128
Study: 24489726

Group type: EXPERIMENTAL
Intervention: 1 minute WBC at -135°C
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2 minutes WBC at -135°C
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 3 minutes WBC at -135°C
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: WBC at -135°C
Number of subjects: 14
Study: 23075398

Group type: EXPERIMENTAL
Intervention: Meal preparation training combined with pedometer-based step count monitoring
Number of subjects: 72
Study: 19845846

Group type: EXPERIMENTAL
Intervention: On-demand tadalafil (N = 2,824)
Number of subjects: 3935

Group type: COMPARATOR
Intervention: Placebo (N = 1,111)
Number of subjects: 3935
Study: 17384766

Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure (500 microg/m(3))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Air-only exposure (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure
Number of subjects: 12
Study: 16300696

Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.2 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study: 12843909

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing
Number of subjects: 15

Group type: COMPARATOR
Intervention: Supine posture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Recumbent 30 degrees posture
Number of subjects: 15
Study: 10051239

Group type: EXPERIMENTAL
Intervention: Systematic search for sinusitis by CT scan (study group)
Number of subjects: 399

Group type: COMPARATOR
Intervention: No systematic search for sinusitis (control group)
Number of subjects: 399
Study: 8554498

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg/day, n = 15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pravastatin (10 or 20 mg, n = 10 and 4 respectively)
Number of subjects: 29
Study: 1785180

Group type: EXPERIMENTAL
Intervention: Live attenuated and inactivated virion divaccines of influenza A (H1N1 + H3N2) and influenza B vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lectin test (microvariant)
Number of subjects: 0
Study: 7178879

Group type: EXPERIMENTAL
Intervention: Mastectomy and chemoimmunotherapy (CT + IT)
Number of subjects: 1985

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1985

Group type: EXPERIMENTAL
Intervention: Retrospective analysis
Number of subjects: 1985
Study: 31453982

Group type: COMPARATOR
Intervention: Paracetamol (2660 mg total over 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29603202

Group type: EXPERIMENTAL
Intervention: Couples-based health behavior intervention
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 348